目的 探討胃蘇顆粒聯(lián)合瑞巴派特治療活動(dòng)期胃潰瘍的臨床療效。方法 選擇2016年6月-2017年5月在同濟(jì)大學(xué)附屬同濟(jì)醫(yī)院接受治療的活動(dòng)期胃潰瘍患者98例，隨機(jī)分為對(duì)照組和治療組，每組各49例。對(duì)照組患者口服瑞巴派特片，0.1 g/次，3次/d。治療組在對(duì)照組治療基礎(chǔ)上口服胃蘇顆粒，餐前30 min口服，5 g/次，3次/d。兩組均連續(xù)治療6周。觀察兩組的中醫(yī)證候療效和內(nèi)鏡療效，比較兩組治療前后臨床癥狀評(píng)分和胃黏膜炎癥積分的變化情況。隨訪3、6個(gè)月，比較兩組的復(fù)發(fā)率。結(jié)果 治療后，對(duì)照組和治療組的中醫(yī)證候總有效率分別為83.67%、97.96%，內(nèi)鏡療效總有效率分別為85.71%、97.96%；兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組上腹痛、腹脹、反酸、噯氣、燒心癥狀評(píng)分、胃黏膜慢性炎癥積分、活動(dòng)性炎癥積分均較治療前顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后，治療組上腹痛、腹脹、反酸、噯氣、燒心癥狀評(píng)分、胃黏膜慢性炎癥積分、活動(dòng)性炎癥積分顯著低于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。隨訪3個(gè)月，對(duì)照組和治療組的復(fù)發(fā)率分別為14.29%、4.08%，兩組比較差異無(wú)統(tǒng)計(jì)學(xué)意義；隨訪6個(gè)月，對(duì)照組和治療組的復(fù)發(fā)率分別為22.45%、6.12%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 胃蘇顆粒聯(lián)合瑞巴派特治療活動(dòng)期胃潰瘍具有較好的臨床療效，可有效減輕臨床癥狀，提高潰瘍愈合質(zhì)量，加快炎癥消退，具有一定的臨床推廣應(yīng)用價(jià)值。

objective To investigate the clinical effect of Weisu Granules combined with rebamipide in treatment of active gastric ulcer. Methods Patients (98 cases) with active gastric ulcer in Tongji Hospital Affiliated to Tongji University from June 2016 to May 2017 were randomly divided into control (49 cases) and treatment (49 cases) groups. Patients in the control group were po administered with Rebamipide Tablets, 0.1 g/time, three times daily. Patients in the treatment group were po administered with Weisu Granules 30 min before the meal on the basis of the control group, 5 g/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the curative effect of TCM syndrome and endoscopic effect were evaluated, and the changes of clinical symptom scores and gastric mucosa inflammation integrals in two groups before and after treatment were compared. Results After treatment, the curative effect of TCM syndrome in the control and treatment groups were 83.67% and 97.96%, respectively, endoscopic effect were 85.71% and 97.96%, respectively, and there was difference between two groups (P < 0.05). After treatment, abdominal pain score, abdominal distension score, acid reflux score, belching score, heartburn score, gastric mucosa chronic inflammation integral, and active inflammatory integral significantly reduced, and the difference was statistically significant in the same group (P < 0.05). After treatment, abdominal pain score, abdominal distension score, acid reflux score, belching score, heartburn score, gastric mucosa chronic inflammation integral, and active inflammatory integral in the treatment group were lower than those in the control group, and there was difference between two groups (P < 0.05). Follow-up 3 months, the recurrence rates in the control and treatment groups were 14.29% and 4.08%, and there was no statistically significant difference between two groups. Follow-up 6 months, the recurrence rates in the control and treatment groups were 22.45% and 6.12%, and there was difference between two groups (P < 0.05). Conclusion Weisu Granules combined with rebamipide has remarkable clinical effect in treatment of active gastric ulcer, and can effectively reduce clinical symptoms, improve the quality of ulcer healing, and accelerate the subtraction of inflammation, which has a certain clinical application value.